Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 11/2016

01.11.2016 | Headache (RB Halker, Section Editor)

Headaches: a Review of the Role of Dietary Factors

verfasst von: Zoya Zaeem, Lily Zhou, Esma Dilli

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Dietary triggers are commonly reported by patients with a variety of headaches, particularly those with migraines. The presence of any specific dietary trigger in migraine patients varies from 10 to 64 % depending on study population and methodology. Some foods trigger headache within an hour while others develop within 12 h post ingestion. Alcohol (especially red wine and beer), chocolate, caffeine, dairy products such as aged cheese, food preservatives with nitrates and nitrites, monosodium glutamate (MSG), and artificial sweeteners such as aspartame have all been studied as migraine triggers in the past. This review focuses the evidence linking these compounds to headache and examines the prevalence of these triggers from prior population-based studies. Recent literature surrounding headache related to fasting and weight loss as well as elimination diets based on serum food antibody testing will also be summarized to help physicians recommend low-risk, non-pharmacological adjunctive therapies for patients with debilitating headaches.
Literatur
1.
Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population—a prevalence study. J Clin Epidemiol. 1991;44:1147–57.PubMedCrossRef
2.
Martelletti P, Birbeck G, Katsarava Z, et al. The Global Burden of Disease survey 2010, lifting the burden and thinking outside-the-box on headache disorders. J Headache Pain. 2013;14(1):13.PubMedPubMedCentralCrossRef
3.
Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache. 2008;48:553–63.PubMedCrossRef
4.
5.••
Orr SL. Diet and nutraceutical interventions for headache management: a review of the evidence. Cephalalgia. 2015. Literature review demonstrated generally poor quality of evidence on the efficacy of diet and nutraceutical management of migraines or other headache disorders.
6.
Martin PR. Behavioral management of migraine headache triggers: learning to cope with triggers. Curr Pain Headache Rep. 2010;14:221–7.PubMedCrossRef
7.
Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain. 1993;53:65–72.PubMedCrossRef
8.
Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992;12:221–8.PubMedCrossRef
9.
Kelman L. Migraine changes with age: IMPACT on migraine classification. Headache. 2006;46:1161–71.PubMedCrossRef
10.
Zivadinov R, Willheim K, Sepic-Grahovac D, et al. Migraine and tension-type headache in Croatia: a population-based survey of precipitating factors. Cephalalgia. 2003;23:336–43.PubMedCrossRef
11.
Cologno D, Torelli P, Manzoni GC. Possible predictive factors in the prognosis of migraine with aura. Cephalalgia. 1999;19:824–30.PubMedCrossRef
12.
Andress-Rothrock D, King W, Rothrock J. An analysis of migraine triggers in a clinic-based population. Headache. 2010;50:1366–70.PubMedCrossRef
13.
Turner LC, Molgaard CA, Gardner CH, et al. Migraine trigger factor in a non-clinical Mexican-American population in San Diego County: implications for etiology. Cephalalgia. 1995;15:523–30.PubMedCrossRef
14.
Robbins L. Precipitating factors in migraine: a retrospective review of 494 patients. Headache. 1994;34:214–6.PubMedCrossRef
15.
Deniz O, Aygul R, Kocak N, et al. Precipitating factors of migraine attacks in patients with migraine with and without aura. Pain Clin. 2004;16:451–6.CrossRef
16.
Constantinides V, Anagnostou E, Bougea A, et al. Migraine and tension-type headache triggers in a Greek population. Arq Neuropsiquiatr. 2015;73:665–9.PubMedCrossRef
17.
Karli N, Zarifoglu M, Calisir N, et al. Comparison of pre-headache phases and trigger factors of migraine and episodic tension-type headache: do they share similar clinical pathophysiology? Cephalalgia. 2005;25:444–51.PubMedCrossRef
18.
Chabriat H, Danchot J, Michel I, et al. Precipitating factors of headache. a prospective study in a national control-matched survey in migraineurs and nonmigraineurs. Headache. 1999;39:335–8.PubMedCrossRef
19.
20.
Ierusalimschy R, Moreira Filho PF. Precipitating factors of migraine attacks in patients with migraine without aura. Arq Neuropsiquiatr. 2002;60:609–13.PubMedCrossRef
21.
Spierings ELH, Ranke AH, Honkoop PC. Precipitating and aggravating factors of migraine versus tension-type headache. Headache. 2001;41:554–8.PubMedCrossRef
22.
Chakravarty A, Mukherjee A, Roy D. Trigger factors in childhood migraine: a clinic-based study from eastern India. J Headache Pain. 2009;10:375–80.PubMedPubMedCentralCrossRef
23.
Yadav RK, Kalita J, Misra UK. A study of triggers of migraine in India. Pain Med. 2010;11:44–7.PubMedCrossRef
24.
Bes A, Kunkel R, Lance J, et al. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.CrossRef
25.
Gibb C, Davies P, Glover V, Steiner T, Rose FC, Sandler M. Chocolate is a migraine-provoking agent. Cephalalgia. 1991;11:93–5.PubMedCrossRef
26.
27.
Van den Bergh V, Amery WK, Waelkens J. Trigger factors in migraine: a study conducted by the Belgian Migraine Society. Headache. 1987;27:191–6.PubMedCrossRef
28.
Ulrich V, Olesen J, Gervil M, et al. Possible risk factors and precipitants for migraine with aura in discordant twin-pairs: a population-based study. Cephalalgia. 2000;20:821–5.PubMedCrossRef
29.
Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine in France. Neurology. 2002;59:232–7.PubMedCrossRef
30.
Peatfield RC, Glover V, Littlewood JT, et al. The prevalence of diet-induced migraine. Cephalalgia. 1984;4:179–83.PubMedCrossRef
31.
Russell MB, Rasmussen BK, Fenger K, et al. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia. 1996;16:239–45.PubMedCrossRef
32.
Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44(1):8–19.PubMedCrossRef
33.
Marcus DA, Scharff L, Turk D, Gourley LM. A double-blind provocative study of chocolate as a trigger of headache. Cephalalgia. 1997;17:855–62.PubMedCrossRef
34.
35.
Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc. 2005;105:110–3.PubMedCrossRef
36.
Fredholm B, Battig K, Holmen J, Nehlig A, Zvartau E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83–133.PubMed
37.
38.
Brown S, Waterer G. Migraine precipitated by adenosine. Med J Aust. 1995;162:389–91.PubMed
39.
40.
Derry C, Derry S, Moore R. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database Syst Rev. 2014: CD009281.
41.
Ona X, Osorio D, Cosp X. Drug therapy for treating post-dural puncture headache. Cochrane Database Syst Rev. 2015;7:CD007887.
42.
Camann WR, Murray RS, Mushlin PS, Lambert DH. Effects of oral caffeine on postdural puncture headache. a double-blind, placebo-controlled trial. Anesth Analg. 1990;70(2):181–4.PubMedCrossRef
43.
Sechzer PH. Post-spinal anesthesia headache treated with caffeine. part II: intracranial vascular distention, a key factor. Curr Therapeut Res Clin Experiment. 1979;26(4):440–8.
44.
Zeger W, Younggren B, Smith L. Comparison of cosyntropin versus caffeine for post-dural puncture headaches: a randomized double-blind trial. World J Emergency Med. 2012;3(3):182–5.CrossRef
45.
Erol DD. The analgesic and antiemetic efficacy of gabapentin or ergotamine/caffeine for the treatment of postdural puncture headache. Adv Med Sci. 2011;56(1):25–9.PubMedCrossRef
46.
Sen J, Sen B. Non-invasive management of post dural puncture headache—a comparison. Bangladesh J Med Sci. 2014;13(02):114–8.CrossRef
47.
Yücel EC, Yücel A, Özyalçin S, Talu GK, Erdine S. Intravenous administration of caffeine sodium benzoate for postdural puncture headache. Reg Anesth Pain Med. 1999;24:51–4.PubMedCrossRef
48.
Strelec S, Prylinski J, Sakert T, Royal M. The efficacy of multi-dose oral caffeine in prevention of post-dural puncture headache. Reg Anesth. 1994;19(2S):79.
49.
Esmaoglu A, Akpinar H, Uqur F. Oral multidose caffeineparacetamol combination is not effective for the prophylaxis of postdural puncture headache. J Clin Anesth. 2005;17:58–61.PubMedCrossRef
50.
Liang J, Wang S. Hypnic headache: a review of clinical features, therapeutic options and outcomes. Cephalalgia. 2014;34:795–805.PubMedCrossRef
51.
Holle D, Naegel S, Krebs S, et al. Clinical characteristics and therapeutic options in hypnic headache. Cephalalgia. 2010;30:1435–42.PubMedCrossRef
52.
Donnet A, Lanteri-Minet M. A consecutive series of 22 cases of hypnic headache in France. Cephalalgia. 2009;29:928–34.PubMedCrossRef
53.
Dodick D, Mosek A, Campbell J. The hypnic (“alarm clock”) headache syndrome. Cephalalgia. 1998;18:152–6.PubMedCrossRef
54.
Pinto CA, Fragoso YD, Souza Carvalho D, et al. Hypnic headache syndrome: clinical aspects of eight patients in Brazil. Cephalalgia. 2002;22:824–7.PubMedCrossRef
55.
Johansson B, Georgiev V, Lindström K, Fredholm BB. A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res. 1997;762:153–64.PubMedCrossRef
56.
Varani K, Portaluppi F, Merighi S, Ongini E, Belardinelli L, Borea PA. Caffeine alters A2A adenosine receptors and their function in human platelets. Circulation. 1999;99:2499–502.PubMedCrossRef
57.
Courturier EGM, Hering R, Steiner TJ. Weekend attacks in migraine patients: caused by caffeine withdrawal?. Cephalalgia. 1992; 12: 99– 100 22b.
58.
Sjaastad O, Bakketeig LS. Caffeine-withdrawal headache. the Vaga study of headache epidemiology. Cephalalgia. 2004;24:241–9.PubMedCrossRef
59.
Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology. 2004;176:1–29.PubMedCrossRef
60.
Fukui PT, Gonçalves TRT, Strabelli CG, et al. Trigger factors in migraine patients. Arq Neuropsiquiatr. 2008;66:494–9.PubMedCrossRef
61.
Hage K, Thoresen K, Stovne LJ, Zwart J. High dietary caffeine consumption is associated with a modest increase in headache prevalence: results from the Head-HUNT Study. J Headache Pain. 2009;10:153–9.CrossRef
62.
Bigal M, Sheftell FD, Rapoport AM, et al. Chronic daily headache: identification of factors associated with induction and transformation. Headache. 2002;42:575–81.PubMedCrossRef
63.
Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache. Neurology. 2004;63:2022–7.PubMedCrossRef
64.
Patrick CH. Alcohol, culture, and society. New York: AMS Press; 1970. p. 26–7.
65.
66.
Rose F. Food and headache. Headache Quart-Curr Treatment Res. 1997;8:319–29.
67.
Aamodt AH, Stovner LJ, Hagen K, et al. Headache prevalence related to smoking and alcohol use. Head-HUNT Stud Eur J Neurol. 2006;13:1233–8.CrossRef
68.
Schürks M, Kurth T, Knorn P, Pageler L, Diener HC. Predictors of hazardous alcohol consumption among patients with cluster headache. Cephalalgia. 2006;26(5):623–7.PubMedCrossRef
69.
Littlewood JT, Glover V, Davies PTG, et al. Red wine as a cause of migraine. Lancet. 1988;1:558–9.PubMedCrossRef
70.
71.••
Rist P, Buring J, Kurth T. Dietary patterns according to headache and migraine status: a cross-sectional study. Cephalalgia. 2015;35:767–75. Cross sectional study within the Women’s Health Study evaluating avoidance of certain diets/foods in migraine and non-migraine headache patients.PubMedCrossRef
72.
Smith I, Kellow AH, Mullen PE, Hanington E. Dietary migraine and tyramine metabolism. Nature (London). 1971;230:246–8.CrossRef
73.
Hanington E. Preliminary report on tyramine headache. BMJ. 1967;2:550–1.CrossRef
74.
Peatfield RC. Relationships between food, wine, and beer-precipitated migrainous headaches. Headache. 1995;35:355–7.PubMedCrossRef
75.
Jansen SC, van Dusseldorp M, Bottema KC, Dubois AEJ. Intolerance to dietary biogenic amines: a review. Ann Allergy Asthma Immunol. 2003;91:233–41.PubMedCrossRef
76.
77.
Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia. 2003;23:877–86.PubMedCrossRef
78.
Sandler M, Youdim MB, Hanington E. A phenylethylamine oxidising defect in migraine. Nature. 1974;250:335–7.PubMedCrossRef
79.
Marcus DA, Scharff L, Turk D, Gourley LM. A double-blind provocative study of chocolate as a trigger of headache. Cephalalgia. 1997;17:855–86.PubMedCrossRef
80.
Roberts HJ. Reactions attributed to aspartame containing products: 551 cases. J Appl Nutr. 1988;40:85–94.
81.
Schiffman SS, Buckley CE, Sampson HA. Aspartame and susceptibility to headache. N Engl J Med. 1987;317:1181.PubMedCrossRef
82.
Sathyapalan T, Thatcher NJ, Hammersley R, et al. Aspartame sensitivity? A double blind randomised crossover study: e0116212. PLoS One. 2015; 10.
83.
Leon AS, Hunninghake DB, Bell C, et al. Safety of long-term doses of aspartame. Arch Intern Med. 1989;1989:2318–24.CrossRef
84.
Van den Eeden SK, Koepsell TD, Longstreth WT, van Belle G, Daling JR, McKnight B. Aspartame ingestion and headaches: a randomized crossover trial. Neurology. 1994;44:1787–93.PubMedCrossRef
85.
Koehler SM, Glaros A. The effect of aspartame on migraine headache. Headache. 1988;28:10–4.PubMedCrossRef
86.
Newman LC, Lipton RB. Migraine MLT-down: an unusual presentation of migraine in patients with aspartame-triggered headaches. Case report. Headache. 2001;41:899–901.PubMedCrossRef
87.
88.
Scharff L, Turk DC, Marcus DA. Triggers of headache episodes and coping responses of headache diagnostic groups. Headache. 1995;35:397–403.PubMedCrossRef
89.
Henderson W, Raskin N. Hot-dog headache: individual susceptibility to nitrite. Lancet. 1972;300:1162–3.CrossRef
90.
Bryan N, Calvert J, Gundewar S, Lefer D. Dietary nitrite restores NO homeostasis and is card ioprotective in endothelial nitric oxide synthase-deficient mice. Free Radic Biol Med. 2008;45:468–74.PubMedPubMedCentralCrossRef
91.
92.
Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther. 2008;120:157–71.PubMedCrossRef
93.
Neyal M, Geyik S, Çekmen M, Balat A, Neyal A. Elevated plasma total nitrite levels may be related to migraine attacks. Gaziantep Med J. 2014;20(4):299–30.CrossRef
94.
Barbanti P, Egeo G, Aurilia C, Fofi L, Della-Morte D. Drugs targeting nitric oxide synthase for migraine treatment. Expert Opin Investig Drugs. 2014;23(8):1141–8.PubMedCrossRef
95.
Kurihara K. Glutamate: from discovery as a food flavor to role as a basic taste (umami). Am J Clin Nutr. 2009;90:719S–22.PubMedCrossRef
96.
97.
Tarasoff L, Kelly MF. Monosodium L-glutamate: a double-blind study and review. Food Chem Toxicol. 1993;31(12):1019–35.PubMedCrossRef
98.
Prawirohardjono W, Dwiprahasto I, Astuti I, Hadiwandowo S, Kristin E, Muhammad M, et al. The administration to Indonesians of monosodium L-glutamate in Indonesian foods: an assessment of adverse reactions in a randomized double-blind, crossover, placebo-controlled study. J Nutr. 2000;130(4S Suppl):1074S–6.PubMed
99.
Tanphaichitr V, Srianujata S, Pothisiri P, Sammasut R, Kulapongse S. Post prandial responses to Thai foods with and without added monosodium L-glutamate. Nutr Rep Int. 1983;28:783–92.
100.
101.
Moghadam MH, Ardalani H, Alehashemi A, Dehkordi MA, Meshkat M. Correlation between severity of migraine attacks and IgE level in peripheral blood. Lab Med. 2016;40:215–9.
102.
Rosario D, Pinto G. Role of gender and serum immunoglobulin E (IGE) levels on severity of migraine. J Clin Diagn Res. 2014;8:57.PubMedPubMedCentral
103.
Cakici M, Bilen S, Motor S, Ak F. Migraine and immunoglobulin E-mediated hypersensitivity. Noropsikiyatri Arsivi-Arch Neuropsychiatr. 2012;49:129–32.CrossRef
104.
Pradalier A, Weinman S, Launay JM, Baron JF, Dry J. Total IgE, specific IgE and prick-tests against foods in common migraine—a prospective study. Cephalalgia. 1983;3:231–4.PubMedCrossRef
105.
Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53(10):1459.PubMedPubMedCentralCrossRef
106.
Arroyave Hernandez CM, Echevarria Pinto M, Hernandez Montiel HL. Food allergy mediated by IgG antibodies associated with migraine in adults. Rev Alerg Mex. 2007;54:162–8.PubMed
107.
Alpay K, Ertaş M, Orhan EK, Üstay DK, Lieners C, Baykan B. Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. Cephalalgia. 2010;30:829–37.PubMedPubMedCentralCrossRef
108.
Aydinlar EI, Dikmen PY, Tiftikci A, et al. IgG‐based elimination diet in migraine plus irritable bowel syndrome. Headache: J Head Face Pain. 2013;53:514–25.CrossRef
109.
Mitchell N, Hewitt C, Jayakody S, et al. Randomised controlled trial of food elimination diet based on IgG antibodies for the prevention of migraine like headaches. Nutr J. 2011;10:85.PubMedPubMedCentralCrossRef
110.
Pascual J, Oterino A. IgG-mediated allergy: a new mechanism for migraine attacks? Cephalalgia. 2010;30:777–9.PubMedCrossRef
111.
Chai NC, Scher AI, Moghekar A, et al. Obesity and headache: part I—a systematic review of the epidemiology of obesity and headache. Headache. 2014;54:219–34.PubMedPubMedCentralCrossRef
112.
Vo M, Ainalem A, Qiu C, Peterlin BL, Aurora SK, Williams MA. Body mass index and adult weight gain among reproductive age women with migraine. Headache. 2011;51:559–69.PubMedPubMedCentralCrossRef
113.
Peterlin BL, Rosso AL, Rapoport AM, Scher AI. Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache. 2010;50:52–62.PubMedCrossRef
114.
Novack V, Fuchs L, Lantsberg L, et al. Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: a case series. Cephalalgia. 2011;31:1336–42.PubMedCrossRef
115.
Bond DS, Vithiananthan S, Nash JM, Thomas JG, Wing RR. Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology. 2011;76:1135–8.PubMedPubMedCentralCrossRef
116.
117.
118.
119.
120.
Spigt MG, Kuijper EC, Schayck CP, et al. Increasing the daily water intake for the prophylactic treatment of headache: a pilot trial. Eur J Neurol. 2005;12:715–8.PubMedCrossRef
121.
Amer M, Woodward M, Appel LJ. Effects of dietary sodium and the DASH diet on the occurrence of headaches: results from randomised multicentre DASH-Sodium clinical trial. BMJ Open. 2014;4:1–7.CrossRef
122.
Ferrara L, Pacioni D, Di Fronzo V, Russo BF, Speranza E, Carlino V, et al. Low-lipid diet reduces frequency and severity of acute migraine attacks. Nutr Metab Cardiovasc Dis. 2015;25(4):370–5.PubMedCrossRef
123.
Bic Z, Blix GG, Hopp HP, et al. The influence of a low-fat diet on incidence and severity of migraine headache. J Womens Health Gend Based Med. 1999;8:623–9.PubMedCrossRef
124.
Schnabel TG. An experience with a ketogenic dietary in migraine. Ann Intern Med. 1928;2:341–7.CrossRef
125.
Maggioni F, Margoni M, Zanchin G. Ketogenic diet in migraine treatment: a brief but ancient history. Cephalalgia. 2011;31:1150–1.PubMedCrossRef
126.
Di Lorenzo C, Coppola G, Sirianni G, et al. Migraine improvement during short lasting ketogenesis: a proof‐of‐concept study. Eur J Neurol. 2015;22:170–7.PubMedCrossRef
127.
Kelman L. The triggers or precipitants of the acute migraine attack. Cephalagia. 2007;27:394–402.CrossRef
Metadaten
Titel
Headaches: a Review of the Role of Dietary Factors
verfasst von
Zoya Zaeem
Lily Zhou
Esma Dilli
Publikationsdatum
01.11.2016
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 11/2016
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0702-1

Weitere Artikel der Ausgabe 11/2016

Current Neurology and Neuroscience Reports 11/2016 Zur Ausgabe

Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation

Headache (RB Halker, Section Editor)

Post-Concussive Syndrome: a Focus on Post-Traumatic Headache and Related Cognitive, Psychiatric, and Sleep Issues

Epilepsy (CW Bazil, Section Editor)

Treatment of Epilepsy in the Elderly

Epilepsy (CW Bazil, Section Editor)

Toward a Mechanistic Understanding of Epileptic Networks

Critical Care (SA Mayer, Section Editor)

Communication, Leadership, and Decision-Making in the Neuro-ICU

Epilepsy (CW Bazil, Section Editor)

Prevention of Epilepsy: Issues and Innovations

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise